Log in

6492 Senhwa Biosciences Inc TPEX · Taiwan

Senhwa Biosciences (6492) news

Senhwa Biosciences Inc is a public biotech or pharmaceutical company listed on TPEX under the ticker 6492, recorded under Taiwan. The directory classifies it as Biotechnology / therapeutics. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Senhwa Biosciences news

We have not published a story on Senhwa Biosciences yet. When there is news, it will appear here.

Questions about Senhwa Biosciences

What is the ticker symbol of Senhwa Biosciences?

Senhwa Biosciences Inc trades under the ticker 6492 on TPEX.

Where is Senhwa Biosciences listed?

Senhwa Biosciences Inc is listed on TPEX.

Which country or territory is Senhwa Biosciences listed under?

Our directory records Senhwa Biosciences Inc under Taiwan.

What does Senhwa Biosciences do?

Our directory classifies Senhwa Biosciences Inc as: Biotechnology / therapeutics. This is a directory classification, not a description of the pipeline.

What is the ISIN of Senhwa Biosciences?

The ISIN recorded for Senhwa Biosciences Inc is TW0006492002.

Does aibio.space cover Senhwa Biosciences?

aibio.space lists Senhwa Biosciences Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Senhwa Biosciences?

Companies in our directory listed in the same country and business area as Senhwa Biosciences: Great Novel Therapeutics Biotech & Medicals, DuoGenic StemCells, TaiRx, Gongwin Biopharm Holdings Co., U-Neuron Biomedical, Vectorite Biomedical.

Investor discussion: Senhwa Biosciences

Members talk about Senhwa Biosciences (6492). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TPEX:6492 on TradingView.

Listing details

Senhwa Biosciences Inc is a public biotech or pharmaceutical company listed on TPEX under the ticker 6492, recorded under Taiwan. The directory classifies it as Biotechnology / therapeutics. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Senhwa Biosciences Inc
Ticker
6492
Listing
TPEX
Country or territory
Taiwan
Business scope
Biotechnology / therapeutics
ISIN
TW0006492002
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.